Rossari Biotech Q2 FY27 consolidated revenue Rs 697.56 cr, PAT Rs 38.91 cr

What the numbers show

• Net margin was 5.58% of revenue, down 71 bps from 6.29%.
• Total expenses rose 20.6% while revenue rose 19.0%.
• Cost of materials accounted for Rs 68.43 cr of the Rs 110.85 cr rise in total expenses (61%).
• Cost of materials took 68.2% of revenue, against 69.5% a year earlier.

• Basis & period: Consolidated statement of financial results, quarter ended 30th September, 2026 vs quarter ended 30th September, 2025.

• Revenue from operations: Rs 697.56 cr (Q2 FY27) vs Rs 586.11 cr (Q2 FY26).

• Other income: Rs 0.599 cr vs Rs 1.60 cr.

• Total income: Rs 698.16 cr vs Rs 587.71 cr.

• Cost of materials consumed: Rs 475.64 cr vs Rs 407.21 cr.

• Purchase of stock-in-trade: Rs 17.79 cr vs Rs 29.39 cr.

• Changes in inventories of finished goods, work-in-progress and stock-in-trade: Rs (16.12) cr vs Rs (35.74) cr.

• Employee benefits expense: Rs 43.62 cr vs Rs 37.80 cr.

• Finance costs: Rs 8.68 cr vs Rs 6.09 cr.

• Depreciation and amortisation expenses: Rs 30.10 cr vs Rs 18.23 cr.

• Other expenses: Rs 89.66 cr vs Rs 75.53 cr.

• Total expenses: Rs 649.36 cr vs Rs 538.51 cr.

• Profit before share of profit of joint venture, associate, exceptional items and tax: Rs 48.80 cr vs Rs 49.20 cr.

• Share of profit of joint venture and associate: Rs 0.469 cr vs Rs 0.468 cr.

• Profit before exceptional items and tax: Rs 49.27 cr vs Rs 49.67 cr.

• Exceptional items: "-" vs "-".

• Profit before tax: Rs 49.27 cr vs Rs 49.67 cr.

• Current tax charge: Rs 12.31 cr vs Rs 16.05 cr.

• Deferred tax charge / (credit): Rs (1.95) cr vs Rs (3.26) cr.

• Total tax expense: Rs 10.36 cr vs Rs 12.80 cr.

• Profit after tax: Rs 38.91 cr vs Rs 36.88 cr.

• Other comprehensive income / (loss): Rs 0.653 cr vs Rs (0.264) cr.

• Total comprehensive income: Rs 39.56 cr vs Rs 36.61 cr.

• Paid up equity share capital: Rs 11.08 cr vs Rs 11.07 cr.

• Earnings per equity share (Basic): Rs 7.02 vs Rs 6.66.

• Earnings per equity share (Diluted): Rs 7.02 vs Rs 6.65.

For Q2 FY27, Rossari Biotech’s consolidated revenue from operations, as per the statement of consolidated financial results for the quarter and half year ended 30th September, 2026, increased to Rs 697.56 cr from Rs 586.11 cr in the corresponding quarter of the previous year. Total income moved to Rs 698.16 cr from Rs 587.71 cr over the same period.

On the cost side, cost of materials consumed rose to Rs 475.64 cr from Rs 407.21 cr, while purchase of stock-in-trade was lower at Rs 17.79 cr compared with Rs 29.39 cr a year earlier. Changes in inventories of finished goods, work-in-progress and stock-in-trade stood at Rs (16.12) cr versus Rs (35.74) cr. Employee benefits expense increased to Rs 43.62 cr from Rs 37.80 cr, finance costs to Rs 8.68 cr from Rs 6.09 cr, and depreciation and amortisation expenses to Rs 30.10 cr from Rs 18.23 cr. Other expenses were Rs 89.66 cr against Rs 75.53 cr in the year-ago quarter.

Profit before share of profit of joint venture, associate, exceptional items and tax was Rs 48.80 cr compared with Rs 49.20 cr in the corresponding prior quarter. After including share of profit of joint venture and associate of Rs 0.469 cr (Rs 0.468 cr a year earlier), profit before exceptional items and tax and profit before tax were both Rs 49.27 cr, marginally lower than Rs 49.67 cr in Q2 FY26. Total tax expense declined to Rs 10.36 cr from Rs 12.80 cr, and profit after tax increased to Rs 38.91 cr from Rs 36.88 cr. Basic and diluted earnings per equity share were Rs 7.02 each, compared with Rs 6.66 and Rs 6.65 respectively in the same quarter of the previous year, based on the figures in the statement of financial results.